Detalhe da pesquisa
1.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 388(11): 1002-1014, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762851
2.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272512
3.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
4.
Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma.
Br J Haematol
; 204(2): 449-454, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036424
5.
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations.
Br J Haematol
; 204(4): 1300-1306, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291707
6.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
7.
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Future Oncol
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38415370
8.
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651976
9.
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Br J Haematol
; 203(5): 736-746, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287117
10.
Bispecific T-cell engagers for treatment of multiple myeloma.
Am J Hematol
; 98 Suppl 2: S13-S21, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702871
11.
Teclistamab in patients with multiple myeloma and impaired renal function.
Am J Hematol
; 98(11): E322-E324, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37614153
12.
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(27): 1823-1840, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492991
13.
Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
Cancer
; 128(2): 292-298, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34495548
14.
How I treat triple-class refractory multiple myeloma.
Br J Haematol
; 198(2): 244-256, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373352
15.
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol
; 199(3): 355-365, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111391
16.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
17.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325490
18.
Revisiting the impact of immunoglobulin isotypes in multiple myeloma.
Ann Hematol
; 101(4): 825-829, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35138417
19.
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Am J Hematol
; 97(9): 1170-1177, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731911
20.
Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
Cancer
; 127(16): 2966-2973, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891351